About Jeil Pharmaceutical
Jeil Pharmaceutical is a publicly listed company based in Seoul (South Korea) founded in 1959. Active pharmaceutical ingredients and intermediates are manufactured. The company has 983 employees. Its chief executive, as recorded, is Seung Soo Han. Its website jeilpharm.co.kr draws about 14 thousand monthly visits. Its focus areas include Biopharma Outsourcing, CDMO, Small Molecules & Peptides and API Production.
Company details
Jeil Pharmaceutical was founded in 1959 and is based in Seoul, South Korea. Operations focus on the manufacturing of active pharmaceutical ingredients and intermediates within the pharmaceutical sector. A GMP-certified laboratory is maintained, encompassing new drug development research, synthesis research, and formulation research facilities. Research is conducted into the full manufacturing processes and ingredients for new drugs, modified drugs, and generic drugs.
- Headquarters Seoul, South Korea
- Employees 983
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Phone•••• ••••
- Website jeilpharm.co.kr/jeilpharm/intro.asp
- Social LinkedIn
- Legal Name Jeil Pharmaceutical Co. Ltd.
- Annual Revenue$392.77 M (USD)-19.49as on Dec 31, 2025
- Net Profit$16.19 M (USD)as on Dec 31, 2025
- EBITDA$22.61 M (USD)as on Dec 31, 2025
- Employee Count983
People of Jeil Pharmaceutical
1 people are tracked at Jeil Pharmaceutical (1 in leadership); the tracked headcount is 983.
| Name | Role | Group |
|---|---|---|
Seung Soo Han | Chairman & CEO | Leadership |
Complete people profiles for Jeil Pharmaceutical
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Jeil Pharmaceutical
Jeil Pharmaceutical is a publicly listed company on the KRX with ticker symbol 271980 in South Korea, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date18 Jul 2017
- Listed onKRX: 271980
- Listed entityJeil Pharmaceutical Co. Ltd.
- Exchange sectorHealth technology
- ISINKR7271980005
- Share price9,740.00 KRW (+0.52% on the day) · 2026-10-14
- Market capitalisation141,197,999,640.00 KRW
- Price to earnings15.1
- EPS (diluted, trailing year)644.46 KRW
- Volume (last session)15,316
Financials of Jeil Pharmaceutical
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 567.24B KRW | 23.38B KRW | 32.65B KRW |
| 2024 | 704.54B KRW | -29.97B KRW | -7.25B KRW |
| 2023 | 726.39B KRW | 5.00B KRW | 18.37B KRW |
| 2022 | 722.23B KRW | -13.09B KRW | -6.54B KRW |
| 2021 | 700.69B KRW | -12.47B KRW | -1.28B KRW |
Detailed financial statements for Jeil Pharmaceutical
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Web traffic of Jeil Pharmaceutical
The website of Jeil Pharmaceutical (jeilpharm.co.kr) receives about 13.5K visits a month and ranks #1,138,393 among all websites worldwide, #1,413 in Biotechnology and Pharmaceuticals.
- Monthly visits13.5K
▼ 35.5% vs previous month
- Unique visitors9.4K
per month
- Global rank#1,138,393
among all websites
- Category rank#1,413
Health · Biotechnology and Pharmaceuticals
- Bounce rate44%
- Pages per visit2.6
- Average visit1 min 20 sec
- DevicesDesktop 37% · Mobile 63%
Websites whose visitors overlap most with Jeil Pharmaceutical. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| dong-wha.co.kr | 100% | 36.6K | #742,957 | View details | |
newsmp.com | newsmp.com | 74% | #330,463 | – | |
| medifonews.com | 74% | #311,780 | View details | ||
| healthinnews.co.kr | 74% | View details | |||
| whosaeng.com | 74% | 150.5K | #310,255 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 11 similar websites and full traffic analytics for Jeil Pharmaceutical
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 11 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Jeil Pharmaceutical
Complete news archive for Jeil Pharmaceutical
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Jeil Pharmaceutical
Jeil Pharmaceutical was founded in 1959.
Jeil Pharmaceutical is headquartered in Seoul, South Korea.
Seung Soo Han is the CEO of Jeil Pharmaceutical, as recorded in our data.
Jeil Pharmaceutical has 983 employees.
Annual revenue of Jeil Pharmaceutical is $392.77M as on Dec 31, 2025.
Jeil Pharmaceutical was founded in 1959 and is based in Seoul, South Korea. Operations focus on the manufacturing of active pharmaceutical ingredients and intermediates within the pharmaceutical sector. A GMP-certified laboratory is maintained, encompassing new drug development research, synthesis research, and formulation research facilities. Research is conducted into the full manufacturing processes and ingredients for new drugs, modified drugs, and generic drugs.
Yes, Jeil Pharmaceutical is publicly traded on KRX under the ticker symbol 271980.